首页> 外文期刊>Haematologica >The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr?m macroglobulinemia | Haematologica
【24h】

The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr?m macroglobulinemia | Haematologica

机译:优化的抗CD20单克隆抗体ublituximab绕过Waldenstr?m巨球蛋白血症的自然杀伤表型特征血液学

获取原文
           

摘要

Waldenstr?m macroglobulinemia (WM) is a rare form of lymphoma characterized by an infiltration of lymphoplasmacytic cells in bone marrow and immunoglobulin M monoclonal gammopathy.1 Despite the introduction of several therapeutic approaches, WM remains incurable.2 Therefore, a better understanding of the mechanisms underlying the immune surveillance around this pathology is still needed to help to develop novel treatment strategies. Natural killer (NK) cells were initially identified through their ability to lyse tumor cells. They express an array of inhibitory, activating, adhesion and cytokine receptors that enable them to kill targets while sparing normal cells.3 NK cells also express the low-affinity Fc receptor (FcγRIIIA/CD16), enabling them to detect antibody-coated target cells and to exert antibody-dependent cell cytotoxicity (ADCC).3 In this study, we focused our attention on NK cells relative to the presence of a circulating B-cell clone in WM patients.The 47 WM patients in the study were diagnosed at the WM French Reference Center Pitié-Salpêtrière Hospital, Paris, France, according to classical biological criteria.1 This study was approved by the institutional ethic committee at the Pitié-Salpêtrière Hospital (CPPIDF6) and all patients provided informed consent prior to participation.Characteristics of the WM patients are summarized in Table 1. They were untreated or had received no treatment during the two years prior to the study. Patients were compared to 20 healthy blood donors from the Etablissement Fran?ais du Sang. In 26 of 47 patients, circulating B-cell clone was detected with a frequency ranging from 0.7% to 63.0% of lymphocytes, corresponding to 0.1% to 17.0% of leukocytes. NK cells, and B and T lymphocytes from freshly harvested whole blood samples were analyzed on the CD45+ lymphocytic gate after staining with an appropriate antibody cocktail (Online Supplementary Appendix), as previously described.4,5 At least 100,000 leukocytes were analyzed on a FACSCanto II (BD Biosciences) to assess the distribution of NK cells, B and T lymphocytes from WM patients, relative to the presence of circulating B cells (as defined in the Online Supplementary Appendix), and compared with healthy controls. A similar absolute number of whole CD3+ T and CD19+ B cells in healthy controls and WM samples are observed (Figure 1A). The absolute value of B cells correlated significantly with the percentage of a circulating B-cell clone (Figure 1B). There was no difference in the distribution of CD3?CD56+ NK cells and both CD56dim and CD56bright subsets between the study groups (Figure 1C and D), indicating that WM does not disturb this immune subset, compared with other hematologic diseases.5–8View this table:View inlineView popupDownload powerpointTable 1. Main characteristics of WM patients.Download figureOpen in new tabDownload powerpointFigure 1. Distribution of lymphocyte subsets and characteristics of natural killer (NK) cells from Waldenstr?m macroglobulinemia (WM) patients with or without circulating B-cell clones. (A) Absolute values of CD3+ T and CD19+ B cells from peripheral blood. (B) Linear regression between absolute value of CD19+ B cells and the percentage of circulating B-cell clones (WM clone). (C) Absolute value and frequency of CD3?CD56+ NK cells from peripheral blood. (D) Expression of CD56bright gated on CD3?CD56+ NK cells. (E) Frequency and mean fluorescence intensity (MFI) of CD16 on CD3?CD56dim NK cells. (F) Frequency and absolute value of CD69 on CD3?CD56dim NK cells. (G) Frequency and absolute value of CD57 on CD3?CD56dim NK cells. (H) Frequency of NKp30 on CD3?CD56dim NK cells. Cells were collected from healthy donors (Ctl; circles) and WM patients without [(clone (?); squares) or with (clone (+); triangles)] circulating B-cell clones (WM clone). Horizontal bars represent median values. Intergroup comparisons were assessed with Kruskal Wallis test and Dunn post test; *P<0.05, **P<0.001, ***P<0.0001
机译:Waldenstrm巨球蛋白血症(WM)是一种罕见的淋巴瘤形式,其特征是骨髓中的淋巴浆细胞浸润和免疫球蛋白M单克隆球蛋白病。1尽管引入了几种治疗方法,但WM仍然是无法治愈的。2因此,人们对WM有了更深入的了解仍需要围绕这种病理学进行免疫监视的机制来帮助开发新的治疗策略。最初通过其裂解肿瘤细胞的能力来鉴定自然杀伤(NK)细胞。它们表达一系列抑制,激活,粘附和细胞因子受体,使其能够杀死靶标,同时保留正常细胞。3NK细胞还表达低亲和力Fc受体(FcγRIIIA/ CD16),从而使它们能够检测抗体包被的靶细胞3这项研究中,我们将注意力集中在NK细胞上,与WM患者中循环B细胞克隆的存在有关。本研究中确诊的47名WM患者是在WM患者中确诊的。根据经典生物学标准,法国巴黎WM法国参考中心皮蒂尔-萨尔普埃雷埃雷医院(1)这项研究得到皮蒂尔-萨尔普埃雷埃雷医院(CPPIDF6)的机构伦理委员会的批准,所有患者在参加研究前均提供了知情同意。表1总结了WM患者。在研究前的两年中,他们未经治疗或未接受任何治疗。将患者与Etablissement Fran?ais du Sang的20名健康献血者进行比较。在47例患者中的26例中,检测到循环B细胞克隆的频率为淋巴细胞的0.7%至63.0%,相当于白细胞的0.1%至17.0%。如前所述,在用适当的抗体混合物(在线补充附录)染色后,在CD45 +淋巴细胞门上分析了新鲜采集的全血样本中的NK细胞以及B和T淋巴细胞。4,5在FACSCanto上至少分析了100,000个白细胞II(BD Biosciences)评估WM患者的NK细胞,B和T淋巴细胞相对于循环B细胞(如在线补充附录中所定义)的分布,并与健康对照进行比较。在健康对照和WM样品中观察到了完整的CD3 + T和CD19 + B细胞的绝对数相似(图1A)。 B细胞的绝对值与循环B细胞克隆的百分比显着相关(图1B)。研究组之间的CD3​​?CD56 + NK细胞以及CD56dim和CD56bright亚群的分布没有差异(图1C和D),表明与其他血液系统疾病相比,WM不会干扰该免疫亚群。5-8表:查看内联视图弹出窗口下载powerpoint表1. WM患者的主要特征。细胞克隆。 (A)来自外周血的CD3 + T和CD19 + B细胞的绝对值。 (B)CD19 + B细胞的绝对值与循环B细胞克隆(WM克隆)的百分比之间的线性回归。 (C)来自外周血的CD3→CD56 + NK细胞的绝对值和频率。 (D)在CD3→CD56 + NK细胞上门控的CD56bright的表达。 (E)CD3?CD56dim NK细胞上CD16的频率和平均荧光强度(MFI)。 (F)在CD3→CD56dim NK细胞上CD69的频率和绝对值。 (G)在CD3→CD56dim NK细胞上CD57的频率和绝对值。 (H)在CD3→CD56dim NK细胞上NKp30的频率。从健康供体(Ctl;圆圈)和WM患者收集细胞,这些患者没有[(克隆(?);正方形)或有(克隆(+);三角形)]循环B细胞克隆(WM克隆)。水平条表示中位数。组间比较采用Kruskal Wallis检验和Dunn post检验进行评估。 * P <0.05,** P <0.001,*** P <0.0001

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号